Cellular and Molecular Aspects of the β-N-Methylamino-l-alanine (BMAA) Mode of Action within the Neurodegenerative Pathway: Facts and Controversy

Toxins (Basel). 2017 Dec 22;10(1):6. doi: 10.3390/toxins10010006.

Abstract

The implication of the cyanotoxin β-N-methylamino-l-alanine (BMAA) in long-lasting neurodegenerative disorders is still a matter of controversy. It has been alleged that chronic ingestion of BMAA through the food chain could be a causative agent of amyotrophic lateral sclerosis (ALS) and several related pathologies including Parkinson syndrome. Both in vitro and in vivo studies of the BMAA mode of action have focused on different molecular targets, demonstrating its toxicity to neuronal cells, especially motoneurons, and linking it to human neurodegenerative diseases. Historically, the hypothesis of BMAA-induced excitotoxicity following the stimulation of glutamate receptors has been established. However, in this paradigm, most studies have shown acute, rather than chronic effects of BMAA. More recently, the interaction of this toxin with neuromelanin, a pigment present in the nervous system, has opened a new research perspective. The issues raised by this toxin are related to its kinetics of action, and its possible incorporation into cellular proteins. It appears that BMAA neurotoxic activity involves different targets through several mechanisms known to favour the development of neurodegenerative processes.

Keywords: BMAA; excitotoxicity; glutamate receptor; intracellular calcium; neurodegenerative disorders; neuromelanin.

Publication types

  • Review

MeSH terms

  • Amino Acids, Diamino / metabolism*
  • Animals
  • Cyanobacteria Toxins
  • Humans
  • Melanins / metabolism
  • Neurodegenerative Diseases / metabolism*
  • Receptors, Glutamate / metabolism

Substances

  • Amino Acids, Diamino
  • Cyanobacteria Toxins
  • Melanins
  • Receptors, Glutamate
  • neuromelanin
  • beta-N-methylamino-L-alanine